Refractory thrombotic thrombocytopenic purpura following influenza vaccination

Anaesthesia

Volumn 64, Issue 4, 2009, Pages 444-446

  Dias, Paul J ^a   Gopal, S ^b  

^a UNIVERSITY HOSPITALS OF NORTH MIDLANDS NHS TRUST   (United Kingdom)

^b NEW CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; PROSTACYCLIN; RITUXIMAB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE; MONOCLONAL ANTIBODY;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; ENZYME DEFICIENCY; HUMAN; INFLUENZA VACCINATION; INTENSIVE CARE; LABORATORY TEST; MALE; PLASMAPHERESIS; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; VON WILLEBRAND FACTOR CLEAVING PROTEINASE DEFICIENCY; BLOOD; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; VACCINATION;

ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLUENZA VACCINES; MALE; MIDDLE AGED; PLASMA EXCHANGE; PLATELET COUNT; PURPURA, THROMBOTIC THROMBOCYTOPENIC; VACCINATION;

EID: 64149122722     PISSN: 00032409     EISSN: 13652044     Source Type: Journal    
DOI: 10.1111/j.1365-2044.2008.05823.x     Document Type: Article

References (11)

1. Moschcovitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proceedings of the New York Pathological Society 1924; 24: 21-24
2. Moake JL. Thrombotic microangiopathies. New England Journal of Medicine 2002; 347: 589-601.
3. Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine (Baltimore) 1966; 45: 139-159
4. Pene F, Vigneau C, Auburtin M, et al. Outcome of severe adult thrombotic microangiopathies in the intensive care unit. Intensive Care Medicine 2005; 31: 71-78
5. Fakhouri F, Vernant J-P, Veyraider A, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 2005; 106: 1932-1937.
6. Limal N, Cacoub P, Sène D, Guichard I, Piette JC. Rituximab for the treatment of thrombotic thrombocytopenic purpura in systemic lupus erythematosus. Lupus 2008; 17: 69-71.
7. Sallah S, Husain A, Wan JY, et al. Rituximab in patients with refractory thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis 2004; 2: 834-836 (Pubitemid 40185722)
8. Rüfer A, Brodmann D, Gregor M, Hovinga JAK, Lämmle B, Wuillemin WA. Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura. Swiss Medical Weekly 2007; 137: 518-524
9. Wraith DC, Goldman M, Lambert PH. Vaccination and autoimmune disease: What is the evidence? The Lancet 2003; 362: 1659-1666
10. Tishler M, Levy O, Amit-Vazina M. Immune thrombocytopenic purpura following influenze vaccination. Israel Vaccine Research Initiative 2006; 8: 322-323 (Pubitemid 43805047)
11. Brown RC, Blecher TE, French EA, Toghill PJ. Thrombotic thrombocytopenic purpura after influenza vaccination. British Medical Journal 1973; 861: 303.